AI Analysis
AI-generated analysis. Always verify with the original filing.
Sangamo Therapeutics reported lower year-over-year revenue and a widened net loss for FY2025, with near-term funding required to sustain operations and advance its pipeline.
Key Takeaways
1GAAP revenue declined 31.6% year-over-year to $39.6 million in FY2025, with future revenues expected to derive primarily from license agreements per management guidance.
2GAAP operating loss widened 16.6% year-over-year to $121.2 million in FY2025, driven by ongoing investments in the company's research and development pipeline.
3GAAP net loss expanded 25.5% year-over-year to $122.9 million in FY2025, while diluted loss per share improved 10.2% to $0.44 per share for the period.
4Net cash used in operating activities totaled $97.2 million in FY2025, resulting in free cash flow of negative $97.3 million for the full fiscal year.
5The company requires substantial additional capital to continue operating as a going concern, with securing a Fabry disease program commercialization partner a critical near-term priority.
6Management expects research and development expenses to rise in coming years if sufficient capital is raised to advance the company's clinical pipeline assets.